Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | ERN1 | O75460 | 3/20 | 0.36 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.36 |
| ▸ | TAB1 | Q15750 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 2/20 | 0.35 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.35 |
| ▸ | CDK1 | P06493 | 1/20 | 0.35 |
| ▸ | CDK4 | P11802 | 1/20 | 0.35 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.35 |
| ▸ | CCND1 | P24385 | 1/20 | 0.35 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.35 |
| ▸ | MAOA | P21397 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16346311 | 0.82 | POLB (0.43) | POLBALDH1A1USP2TSHRHSD17B10 | |
| SCHEMBL16346510 | 0.81 | ALDH1A1 (0.50) | POLBALDH1A1USP2TSHRHSD17B10 | |
| SCHEMBL16948226 | 0.80 | POLB (0.40) | POLBALDH1A1USP2TSHRHSD17B10 | |
| SCHEMBL11980573 | 0.76 | ALDH1A1 (0.42) | POLBALDH1A1USP2TSHRHSD17B10 | |
| SCHEMBL16346255 | 0.76 | POLB (0.63) | POLBALDH1A1USP2TSHRHSD17B10 | |
| SCHEMBL16346247 | 0.73 | ALDH1A1 (0.35) | POLBALDH1A1USP2TSHRHSD17B10 | |
| SCHEMBL16346249 | 0.71 | LTB4R (0.35) | POLBALDH1A1ERN1LMNAGAA | |
| SCHEMBL16347957 | 0.69 | TLR8 (0.38) | ALDH1A1LMNAHPGDHTTMEN1 | |
| SCHEMBL16347637 | 0.69 | ERN1 (0.32) | POLBALDH1A1ERN1LMNAGAA | |
| SCHEMBL10188484 | 0.68 | ALDH1A1 (0.48) | POLBALDH1A1USP2TSHRHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10442769-B2 | Process for the preparation of intermediate of dolutegravir | HETERO RESEARCH FOUNDATION (IN) | 2019-10-15 | — | — | US | claimed |
| EP-3016935-B1 | PROCESS FOR THE PREPARATION OF INTERMEDIATE OF DOLUTEGRAVIR | HETERO RESEARCH FOUNDATION (IN) | 2018-09-05 | — | — | EP | claimed |
| US-20180148412-A1 | PROCESS FOR THE PREPARATION OF INTERMEDIATE OF DOLUTEGRAVIR | HETERO RESEARCH FOUNDATION (IN) | 2018-05-31 | — | — | US | claimed |
| US-9963430-B2 | Process for the preparation of intermediate of dolutegravir | HETERO RESEARCH FOUNDATION (IN) | 2018-05-08 | — | — | US | claimed |
| US-20170334858-A1 | PROCESS FOR THE PREPARATION OF INTERMEDIATE OF DOLUTEGRAVIR | HETERO RESEARCH FOUNDATION (IN) | 2017-11-23 | — | — | US | claimed |
| EP-3016935-A2 | PROCESS FOR THE PREPARATION OF INTERMEDIATE OF DOLUTEGRAVIR | Hetero Research Foundation (IN) | 2016-05-11 | — | — | EP | claimed |
| WO-2015001572-A2 | PROCESS FOR THE PREPARATION OF INTERMEDIATE OF DOLUTEGRAVIR | HETERO RESEARCH FOUNDATION (IN) | 2015-01-08 | — | — | WO | claimed |
| US-10442769-B2 | Process for the preparation of intermediate of dolutegravir | HETERO RESEARCH FOUNDATION (IN) | 2019-10-15 | — | — | US | disclosed |
| US-10442769-B2 | Process for the preparation of intermediate of dolutegravir | HETERO RESEARCH FOUNDATION (IN) | 2019-10-15 | — | — | US | disclosed |
| US-10301321-B2 | Process for the preparation of dolutegravir and pharmaceutically acceptable salts thereof | LAURUS LABS LIMITED (IN) | 2019-05-28 | — | — | US | disclosed |
| EP-3016935-B1 | PROCESS FOR THE PREPARATION OF INTERMEDIATE OF DOLUTEGRAVIR | HETERO RESEARCH FOUNDATION (IN) | 2018-09-05 | — | — | EP | disclosed |
| US-20180155364-A1 | NOVEL PROCESS FOR THE PREPARATION OF DOLUTEGRAVIR AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | LAURUS LABS LIMITED (IN) | 2018-06-07 | — | — | US | disclosed |
| US-20180155364-A1 | NOVEL PROCESS FOR THE PREPARATION OF DOLUTEGRAVIR AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | LAURUS LABS LIMITED (IN) | 2018-06-07 | — | — | US | disclosed |
| US-20170334858-A1 | PROCESS FOR THE PREPARATION OF INTERMEDIATE OF DOLUTEGRAVIR | HETERO RESEARCH FOUNDATION (IN) | 2017-11-23 | — | — | US | disclosed |
| US-20160333026-A1 | NOVEL PROCESS FOR THE PREPARATION OF DOLUTEGRAVIR AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | LAURUS LABS PRIVATE LIMITED (IN) | 2016-11-17 | — | — | US | disclosed |
| US-20160333026-A1 | NOVEL PROCESS FOR THE PREPARATION OF DOLUTEGRAVIR AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | LAURUS LABS PRIVATE LIMITED (IN) | 2016-11-17 | — | — | US | disclosed |
| EP-3016935-A2 | PROCESS FOR THE PREPARATION OF INTERMEDIATE OF DOLUTEGRAVIR | Hetero Research Foundation (IN) | 2016-05-11 | — | — | EP | disclosed |
| WO-2015110897-A2 | NOVEL PROCESS FOR THE PREPARATION OF DOLUTEGRAVIR AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | LAURUS LABS PRIVATE LIMITED (IN) | 2015-07-30 | — | — | WO | disclosed |
| WO-2015001572-A2 | PROCESS FOR THE PREPARATION OF INTERMEDIATE OF DOLUTEGRAVIR | HETERO RESEARCH FOUNDATION (IN) | 2015-01-08 | — | — | WO | disclosed |
| WO-2015001572-A2 | PROCESS FOR THE PREPARATION OF INTERMEDIATE OF DOLUTEGRAVIR | HETERO RESEARCH FOUNDATION (IN) | 2015-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170334858-A1 | PROCESS FOR THE PREPARATION OF INTERMEDIATE OF DOLUTEGRAVIR | CYP3A4, DHPS, MVD | POLB 73/4885ALDH1A1 1199/4885USP2 3570/4885 |
| US-20180148412-A1 | PROCESS FOR THE PREPARATION OF INTERMEDIATE OF DOLUTEGRAVIR | CYP3A4, DHPS, MVD | POLB 73/4885ALDH1A1 1199/4885USP2 3570/4885 |
| US-10301321-B2 | Process for the preparation of dolutegravir and pharmaceutically acceptable salts thereof | CYP3A5, CYP3A43, CYP3A4 | POLB 986/4885ALDH1A1 1691/4885USP2 4586/4885 |
| US-20180155364-A1 | NOVEL PROCESS FOR THE PREPARATION OF DOLUTEGRAVIR AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | CYP3A5, SAMHD1, CYP3A43 | POLB 1264/4885ALDH1A1 1838/4885USP2 4550/4885 |
| US-10442769-B2 | Process for the preparation of intermediate of dolutegravir | CYP3A4, DHPS, MVD | POLB 73/4885ALDH1A1 1199/4885USP2 3570/4885 |
| US-20160333026-A1 | NOVEL PROCESS FOR THE PREPARATION OF DOLUTEGRAVIR AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | CYP3A5, SAMHD1, CYP3A43 | POLB 1264/4885ALDH1A1 1838/4885USP2 4550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.